HOME > REGULATORY
REGULATORY
- LDP Project Team Proposes Review of Coverage Rules to Fuel Biosimilar Use
May 13, 2025
- Industry Renews Opposition to CEA Expansion at LDP Hearing
May 13, 2025
- MHLW Panel OKs Outline of Policy Directions to Spur Clinical Trials
May 13, 2025
- MHLW to Help Match Domestic Firms with Overseas Originators to Fight Drug Loss
May 12, 2025
- MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary
May 12, 2025
- MHLW Official Explains Scope of Expanded Conditional Approval System at Diet
May 12, 2025
- Ruling Bloc, Ishin Reach No Deal on Coverage of OTC-Like Drugs
May 8, 2025
- MHLW to Set Up Special Panel for High-Cost Medical Expense Benefit Program
May 7, 2025
- AMED to Strengthen Coordination Between Projects: New President
May 7, 2025
- Japan Govt OKs Economic Package to Counter US Tariff Impact
April 28, 2025
- ASKA’s Contraceptive, Vabysmo Label Expansion Now in Line for Japan Approval
April 28, 2025
- MHLW/PMDA, FDA Philippines to Boost Regulatory Cooperation
April 28, 2025
- LDP Members Raise No Call for Tax Cuts, Fret Inflationary Impact on Medical Facilities: Fiscal Reform HQ
April 25, 2025
- Japan to Buttress Regulatory Communication Efforts for Drug Originators Overseas
April 25, 2025
- “Time to Revise” Fee Premiums for Generic Use: Chuikyo Payer Rep
April 25, 2025
- LDP Group Calls for Keeping Health Coverage for Pain Relief Patches
April 25, 2025
- MHLW to Present Estimate on Coverage Removal of OTC-Like Meds at 3-Party Talks
April 24, 2025
- MOF’s Spring Debate Puts Special Focus on CEA, More Aggressive Re-Pricing Eyed
April 24, 2025
- Epkinly to Face Price Cuts under CEA Scheme
April 24, 2025
- Biosimilars Should Be Mentioned in Honebuto: LDP Pharma Affairs Panel Chair
April 23, 2025
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…